home / stock / vir / vir articles
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results...
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. Shares of Carvana Co. (NYSE: CVNA) rose sharply d...
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023. ...
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that eight abstracts highlighting new data...
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate updat...
U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria.&nbs...
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, down from $2...
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. Dig...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NYSE Market:
2024-03-26 14:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-15 11:30:03 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for VIR on March 15, 2024 10:00AM ET. The previous analyst recommendation was Underperform. VIR was trading at $10.54 at issue of the analyst recommendation. The overall analyst consensus :...
2024-03-15 11:30:03 ET J.P. Morgan analyst issues BUY recommendation for VIR on March 15, 2024 10:00AM ET. The previous analyst recommendation was Buy. VIR was trading at $10.54 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...